Worsening kidney function in decompensated heart failure: Treat the heart, dont mind the kidney

European Heart Journal

Volumn 32, Issue 20, 2011, Pages 2476-2478

  Ruggenenti, Piero ^a,b   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; TOLVAPTAN;

BODY WEIGHT; COMORBIDITY; DIALYSIS; GLOMERULUS FILTRATION RATE; HEART FAILURE; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PLACEBO EFFECT; PRIORITY JOURNAL; REVIEW; ULTRAFILTRATION;

BENZAZEPINES; CARDIO-RENAL SYNDROME; HOSPITALIZATION; HUMANS; RECEPTORS, VASOPRESSIN; VENTRICULAR DYSFUNCTION, LEFT;

EID: 80054753558     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr242     Document Type: Review

References (15)

1. Blair JEA, Pang PS, Schrier RW, Metra M, Traver B, Cook T, Campia U, Ambrosy A, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Konstam MA, Gheorghiade M. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J 2011;32:2563-2572. First published on 23 July 2011. doi:10.1093/eurheartj/ehr238.
2. Merrill AJ. Edema and decreased renal blood flow in patients with chronic congestive heart failure; evidence of forward failure as the primary cause of edema. J Clin Invest 1946;25:389-400.
3. Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs 1990;39 Suppl 4:10-21; discussion 22-14. (Pubitemid 20182861)
4. Ichikawa I, Pfeffer JM, Pfeffer MA, Hostetter TH, Brenner BM. Role of angiotensin II in the altered renal function of congestive heart failure. Circ Res 1984;55: 669-675. (Pubitemid 15176962)
5. Bock JS, Gottlieb SS. Cardiorenal syndrome: New perspectives. Circulation 2010; 121:2592-2600.
6. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: Accuracy in good health and in chronic kidney disease. Ann Intern Med 2004;141:929-937.
7. McCullough PA. Cardiorenal risk: An important clinical intersection. Rev Cardiovasc Med 2002;3:71-76. (Pubitemid 34661885)
8. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 1992;70:479-487.
9. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-1930. (Pubitemid 16062649)
10. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: Prognostic and therapeutic implications from a prospective cohort study. Circulation 2004;109:1004-1009. (Pubitemid 38282853)
11. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-1951. (Pubitemid 39447135)
12. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998;352:1252-1256. (Pubitemid 28470337)
13. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
14. Ruggenenti P, Perticucci E, Cravedi P, Gambara V, Costantini M, Sharma SK, Perna A, Remuzzi G. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 2008;19:1213-1224.
15. Remuzzi G, Ruggenenti P, Perna A, Dimitrov BD, de Zeeuw D, Hille DA, Shahinfar S, Carides GW, Brenner BM. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 2004;15:3117-3125. (Pubitemid 39578844)